Andra AP fonden Sells 30,680 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Andra AP fonden reduced its Alnylam Pharmaceuticals stake by 35.4%, selling 30,680 shares in the second quarter and retaining 56,017 shares valued at approximately $16.9 million.
• Institutional ownership remains high at 92.97%, while several other investors increased their positions in the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $367.20, despite some firms lowering their targets.

Andra AP fonden trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,017 shares of the biopharmaceutical company's stock after selling 30,680 shares during the period. Andra AP fonden's holdings in Alnylam Pharmaceuticals were worth $16,863,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Bank of Nova Scotia increased its stake in Alnylam Pharmaceuticals by 0.6% in the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company's stock worth $2,580,000 after purchasing an additional 49 shares during the period. Prestige Wealth Management Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 30.6% during the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 53 shares during the period. Glenmede Trust Co. NA grew its holdings in shares of Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company's stock worth $242,000 after purchasing an additional 56 shares during the last quarter. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $25,000. Finally, Parallel Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 7.9% in the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company's stock worth $295,000 after purchasing an additional 65 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ALNY. Chardan Capital reiterated a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating on the stock in a research report on Friday, July 31st. Citigroup lowered their price objective on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 31st. Finally, TD Cowen reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $367.20.

Alnylam Pharmaceuticals Stock Up 3.0%

ALNY stock opened at $251.65 on Wednesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The firm has a market cap of $33.67 billion, a PE ratio of 46.78 and a beta of 0.31. The business has a 50 day moving average of $245.82 and a 200 day moving average of $284.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analysts' expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company's quarterly revenue was up 66.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.51) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.